CBLL1 and cancer: Hakai contains a unique and novel HYB (Hakai pTyr-binding) domain that forms a phosphotyrosine-binding pocket, consisting of a pair of monomers arranged in an anti-parallel configuration, which converts Hakai in an excellent drug target against cancer [25,26].